| 臺大學術典藏 |
2021-08-31T06:29:21Z |
Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients
|
Yang S.-H.; Guo J.-C.; Hsu C.; Kuo S.-H.; Tien Y.-W.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:21Z |
Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population
|
Lin C.-H.; Yap Y.S.; Lee K.-H.; Im S.-A.; Naito Y.; Yeo W.; Ueno T.; Kwong A.; Li H.; Huang S.-M.; Leung R.; Han W.; Tan B.; Hu F.-C.; Huang C.-S.; ANN-LII CHENG; Lu Y.-S.; Asian Breast Cancer Cooperative Group |
| 臺大學術典藏 |
2021-08-31T06:29:21Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:21Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:20Z |
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma
|
Alsina A.; Kudo M.; Vogel A.; ANN-LII CHENG; Tak W.Y.; Ryoo B.-Y.; Evans T.R.J.; L?pez L?pez C.; Daniele B.; Misir S.; Ren M.; Izumi N.; Qin S.; Finn R.S. |
| 臺大學術典藏 |
2021-08-31T06:29:20Z |
Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western Populations
|
Chen C.-H.; Lu Y.-S.; ANN-LII CHENG; Huang C.-S.; Kuo W.-H.; Wang M.-Y.; Chao M.; Chen I.-C.; Kuo C.-W.; Lu T.-P.; Lin C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:20Z |
Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection
|
Tsou H.-H.; Yang H.-C.; Hsiao C.-F.; Hsiung C.A.; Liu T.-W.; Chuang M.-H.; Wu H.-Y.; Hsu Y.-T.; Tsui C.-W.; Chen P.-J.; ANN-LII CHENG; Hsu C.; Taiwan Cooperative Oncology Group |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma
|
Shen Y.-C.; Hsu C.-L.; Jeng Y.-M.; Ho M.-C.; Ho C.-M.; Yeh C.-P.; Yeh C.-Y.; Hsu M.-C.; Hu R.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
Milestones in the pathogenesis and management of primary liver cancer
|
Nault J.-C.; ANN-LII CHENG; Sangro B.; Llovet J.M. |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; ANN-LII CHENG; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYnote-240: A Randomized, Double-Blind, Phase III Trial
|
Finn R.S.; Ryoo B.-Y.; Merle P.; Kudo M.; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Knox J.; Daniele B.; Ebbinghaus S.W.; Chen E.; Siegel A.B.; Zhu A.X.; ANN-LII CHENG; KEYnote-240 investigators |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
|
ANN-LII CHENG; Hsu C.; Chan S.L.; Choo S.-P.; Kudo M. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.; Martinelli E.; ANN-LII CHENG; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Shen Y.-C.; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; ANN-LII CHENG; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
|
Kelley R.K.; Mollon P.; Blanc J.-F.; Daniele B.; Yau T.; ANN-LII CHENG; Valcheva V.; Marteau F.; Guerra I.; Abou-Alfa G.K. |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
|
Finn R.S.; Qin S.; Ikeda M.; Galle P.R.; Ducreux M.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.O.; Li D.; Verret W.; Xu D.-Z.; Hernandez S.; Liu J.; Huang C.; Mulla S.; Wang Y.; Lim H.Y.; Zhu A.X.; ANN-LII CHENG; IMbrave150 Investigators |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival
|
Chen T.W.-W.; Jan I.-S.; Chang D.-Y.; Lin C.-H.; Chen I.-C.; Chen H.-M.; ANN-LII CHENG; Lu Y.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
IMbrave 050: A Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation
|
Hack S.P.; Spahn J.; Chen M.; ANN-LII CHENG; Kaseb A.; Kudo M.; Lee H.C.; Yopp A.; Chow P.; Qin S. |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
|
Kudo M.; Han K.-H.; Ye S.-L.; Zhou J.; Huang Y.-H.; Lin S.-M.; Wang C.-K.; Ikeda M.; Chan S.L.; Choo S.P.; Miyayama S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:16Z |
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
|
Kelley R.K.; Ryoo B.-Y.; Merle P.; Park J.-W.; Bolondi L.; Chan S.L.; Lim H.Y.; Baron A.D.; Parnis F.; Knox J.; Cattan S.; Yau T.; Lougheed J.C.; Milwee S.; El-Khoueiry A.B.; ANN-LII CHENG; Meyer T.; Abou-Alfa G.K. |
| 臺大學術典藏 |
2021-08-31T06:29:16Z |
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design
|
Kelley R.K.; W Oliver J.; Hazra S.; Benzaghou F.; Yau T.; ANN-LII CHENG; Rimassa L. |
| 臺大學術典藏 |
2021-08-31T06:29:16Z |
A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue
|
Tsai H.-J.; Tai J.J.; Chen L.-T.; Wu M.-S.; Yeh K.-H.; Lin C.-W.; Wang T.-E.; Wang H.-P.; Yu F.-J.; Liou J.-M.; Hsiao C.-F.; Cheng T.-Y.; Yeh H.-J.; Ko C.-W.; Chen M.-J.; Lo G.-H.; Hsu P.-I.; Chang C.-S.; Hwang W.-S.; Chuang S.-S.; Lee H.-W.; Shun C.-T.; Chiu C.-F.; Wang W.-M.; Hsieh C.-Y.; Liu T.-W.; Lin J.-T.; Kuo S.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:15Z |
A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women
|
Tsai M.-S.; Chang S.-H.; Kuo W.-H.; Kuo C.-H.; Li S.-Y.; Wang M.-Y.; Chang D.-Y.; Lu Y.-S.; Huang C.-S.; ANN-LII CHENG; Lin C.-H.; Chen P.-C. |
| 臺大學術典藏 |
2021-08-31T06:29:15Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; ANN-LII CHENG; Lee R.-C.; Chao Y.; Hsu C. |
| 臺大學術典藏 |
2021-08-31T06:29:15Z |
Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. Reply
|
Finn R.S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:14Z |
Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer
|
Kasper S.; Foch C.; Messinger D.; Esser R.; Lamy F.-X.; Rothe V.; Chen W.; ANN-LII CHENG; Rouyer M.; Brodowicz T.; Zielinski C. |
| 臺大學術典藏 |
2021-08-31T06:29:14Z |
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
|
Sangro B.; Melero I.; Wadhawan S.; Finn R.S.; Abou-Alfa G.K.; ANN-LII CHENG; Yau T.; Furuse J.; Park J.-W.; Boyd Z.; Tang H.T.; Shen Y.; Tschaika M.; Neely J.; El-Khoueiry A. |
| 臺大學術典藏 |
2021-08-31T06:29:14Z |
Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
|
Kelley R.K.; Meyer T.; Rimassa L.; Merle P.; Park J.-W.; Yau T.; Chan S.L.; Blanc J.-F.; Tam V.C.; Tran A.; Dadduzio V.; Markby D.W.; Kaldate R.; ANN-LII CHENG; El-Khoueiry A.B.; Abou-Alfa G.K. |
| 臺大學術典藏 |
2021-08-31T06:29:14Z |
Comparison of clinicopathological features and treatment outcomes in aggressive primary intestinal B- and T/NK-cell lymphomas
|
Ma W.-L.; Yeh K.-H.; Yao M.; Tang J.-L.; Lin C.-W.; Wang Y.-T.; Yeh Y.-C.; Wang H.-P.; ANN-LII CHENG; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:13Z |
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
|
Ryoo B.-Y.; ANN-LII CHENG; Ren Z.; Kim T.-Y.; Pan H.; Rau K.-M.; Choi H.J.; Park J.-W.; Kim J.H.; Yen C.J.; Lim H.Y.; Zhou D.; Straub J.; Scheele J.; Berghoff K.; Qin S. |
| 臺大學術典藏 |
2021-08-31T06:29:13Z |
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYnote-240
|
Ryoo B.-Y.; Merle P.; Kulkarni A.S.; ANN-LII CHENG; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Daniele B.; Norquist J.M.; Chen E.; Siegel A.B.; Zhu A.X.; Finn R.S.; Kudo M. |
| 臺大學術典藏 |
2021-08-31T06:29:13Z |
Pursuing efficacious systemic therapy for hepatocellular carcinoma
|
ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:13Z |
An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma
|
Shao Y.-Y.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-15T00:08:34Z |
Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
|
Chen, I. Chun; Hu, Fu Chang; CHING-HUNG LIN; Huang, Shu Min; Chang, Dwan Ying; ANN-LII CHENG; YEN-SHEN LU |
| 臺大學術典藏 |
2021-08-15T00:08:05Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
BANG-BIN CHEN; YU-YUN SHAO; Lin, Zhong Zhe; CHIH-HUNG HSU; ANN-LII CHENG; CHIUN HSU; PO-CHIN LIANG; TIFFANY TING-FANG SHIH |
| 臺大學術典藏 |
2021-08-06T03:26:51Z |
Targeted Therapy for Hepatocellular Carcinoma
|
CHIUN HSU; Ying-Chun Shen; Ann-Lii Cheng |
| 臺大學術典藏 |
2021-07-15T05:31:28Z |
Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
|
Chia-Lang Hsu; DA-LIANG OU; Bai, Li Yuan; Chen, Chia Wei; Lin, Li; Huang, Shiu Feng; ANN-LII CHENG; YUNG-MING JENG; CHIUN HSU |
| 臺大學術典藏 |
2021-05-27T03:48:21Z |
Targeted Therapy for Renal Cell Carcinoma
|
Yu-Chieh Tsai; Ann-Lii Cheng; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-05-21T11:40:36Z |
Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort
|
Chen, Kuo Hsing; LIANG-IN LIN; Yuan, Chang Tsu; LI-HUI TSENG; Chao, Yu Liang; Liang, Yi Hsin; JIN-TUNG LIANG; BEEN-REN LIN; ANN-LII CHENG; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-04-21T23:30:44Z |
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
|
DA-LIANG OU; Chen, Chia Wei; Chia-Lang Hsu; Chung, Chih Hung; Feng, Zi Rui; Lee, Bin Shyun; ANN-LII CHENG; Yang, Muh Hwa; CHIUN HSU |
| 臺大學術典藏 |
2019-10-23T13:07:16Z |
Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer
|
CHUN-WEI WANG;SUNG-HSIN KUO;ANN-LII CHENG;KENG-HSUEH LAN;YU-HSUAN CHEN;Wei, Ming Feng;Tzeng, Yi Shin; YU-HSUAN CHEN; Tzeng, Yi Shin; Wei, Ming Feng; KENG-HSUEH LAN; ANN-LII CHENG; SUNG-HSIN KUO; CHUN-WEI WANG |
| 臺大學術典藏 |
2019-10-16T08:39:08Z |
Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma
|
Lin, Zhong-Zhe;Hsu, Chiun;Yung-Ming Jeng;Hu, Fu-Chang;Pan, Hung-Wei;Yao-Ming Wu;Hsu, Hey-Chi;Ann-Lii Cheng; Lin, Zhong-Zhe; Hsu, Chiun; YUNG-MING JENG; Hu, Fu-Chang; Pan, Hung-Wei; YAO-MING WU; Hsu, Hey-Chi; ANN-LII CHENG |
| 臺大學術典藏 |
2019-09-11T03:49:53Z |
Prognostic significance of tumor-infiltrating lymphocytes in patients with operable tongue cancer
|
ANN-LII CHENG;SUNG-HSIN KUO;YIH-LEONG CHANG;Huang, Bing-Shen;HSIANG-KUANG LIANG;KENG-HSUEH LAN;CHUN-WEI WANG;CHEN-TU WU;WAN-YU CHEN; WAN-YU CHEN; CHEN-TU WU; CHUN-WEI WANG; KENG-HSUEH LAN; HSIANG-KUANG LIANG; Huang, Bing-Shen; YIH-LEONG CHANG; SUNG-HSIN KUO; ANN-LII CHENG |
| 臺大學術典藏 |
2019-09-09T00:55:32Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu, Li Chun;YU-YUN SHAO;Shen, Ying Chun;Hsu, Chiun;YI-PING HUNG;CHIH-HUNG HSU;Liu, Tsung Hao;ANN-LII CHENG;Guo, Jhe Cyuan;Yen, Chia Jui;Chang, Chun Jung;I-LUN SHIH;Chao, Yee; Chao, Yee; I-LUN SHIH; Chang, Chun Jung; Yen, Chia Jui; Guo, Jhe Cyuan; ANN-LII CHENG; Liu, Tsung Hao; CHIH-HUNG HSU; YI-PING HUNG; Hsu, Chiun; Shen, Ying Chun; YU-YUN SHAO; Lu, Li Chun |
| 臺大學術典藏 |
2019-09-09T00:55:12Z |
Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian versus Western Populations
|
Chen, I. Chun;CHING-HUNG LIN;Wang, Ming Yang;WEN-HUNG KUO;Lu, Yen Shen;TZU-PIN LU;CHAO-MING FU;ANN-LII CHENG;CHUN-WEI KUO;CHIUN-SHENG HUANG;Chen, Ching Hsuan; Chen, Ching Hsuan; CHIUN-SHENG HUANG; CHUN-WEI KUO; ANN-LII CHENG; CHAO-MING FU; TZU-PIN LU; Lu, Yen Shen; WEN-HUNG KUO; Wang, Ming Yang; CHING-HUNG LIN; Chen, I. Chun |
| 臺大學術典藏 |
2019-08-29T07:31:06Z |
Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection
|
Tsou, Hsiao-Hui;Hung-Chih Yang;Hsiao, Chin-Fu;Hsiung, Chao A;Liu, Tsang-Wu;Chuang, Mei-Hsing;Wu, Hsiao-Yu;Hsu, Ya-Ting;Tsui, Chiung-Wen;Pei-Jer Chen;Ann-Lii Cheng;Hsu, Chiun; Tsou, Hsiao-Hui; HUNG-CHIH YANG; Hsiao, Chin-Fu; Hsiung, Chao A; Liu, Tsang-Wu; Chuang, Mei-Hsing; Wu, Hsiao-Yu; Hsu, Ya-Ting; Tsui, Chiung-Wen; PEI-JER CHEN; ANN-LII CHENG; Hsu, Chiun |
| 臺大學術典藏 |
2019-08-29T03:43:35Z |
Autocleavage of the paracaspase MALT1 at Arg-781 attenuates NF-κB signaling and regulates the growth of activated B-cell like diffuse large B-cell lymphoma cells
|
Wu, Chun-Hsien;Yang, Yu-Hsuan;Mei-Ru Chen;Ching-Hwa Tsai;Ann-Lii Cheng;Shin-Lian Doong; Wu, Chun-Hsien; Yang, Yu-Hsuan; MEI-RU CHEN; CHING-HWA TSAI; ANN-LII CHENG; SHIN-LIAN DOONG |
| 臺大學術典藏 |
2019-08-05T08:19:51Z |
Novel Insights of Lymphomagenesis of Helicobacter pylori-Dependent Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
|
ANN-LII CHENG;Chen, Li-Tzong;PING-NING HSU;CHUNG-WU LIN;KUN-HUEI YEH;MING-SHIANG WU;SUNG-HSIN KUO; SUNG-HSIN KUO; MING-SHIANG WU; KUN-HUEI YEH; CHUNG-WU LIN; PING-NING HSU; Chen, Li-Tzong; ANN-LII CHENG |
| 臺大學術典藏 |
2019-08-05T07:56:05Z |
The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21)
|
ANN-LII CHENG;Chen, Li-Tzong;PING-NING HSU;MING-SHIANG WU;CHIA-TUNG SHUN;Wei, Ming-Feng;Lee, Hsiao-Wei;KUN-HUEI YEH;CHUNG-WU LIN;Tsai, Hui-Jen;SUNG-HSIN KUO; SUNG-HSIN KUO; Tsai, Hui-Jen; CHUNG-WU LIN; KUN-HUEI YEH; Lee, Hsiao-Wei; Wei, Ming-Feng; CHIA-TUNG SHUN; MING-SHIANG WU; PING-NING HSU; Chen, Li-Tzong; ANN-LII CHENG |
